1. Adjuvant Chemotherapy for Patients with T2N0M0 NSCLC
Daniel Morgensztern, MD, Lingling Du, MD, Saiama N. Waqar, MD, Aalok Patel, MD, Pamela Samson, MD, Siddhartha Devarakonda, MD, Feng Gao, PhD, Cliff G. Robinson, MD, Jeffrey Bradley, MD, Maria Baggstrom, MD, Ashiq Masood, MD, Ramaswamy Govindan, MD, Varun Puri, MD, MSCI 
Journal of Thoracic Oncology 
Volume 11, Issue 10, Pages (October 2016)
DOI: /j.jtho
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Kaplan-Meier survival curves according to tumor size and use of chemotherapy: (A) tumor size 3.1 to 3.9 cm, (B) tumor size 4 to 4.9 cm, (C) tumor size 5 to 5.9 cm, and (D) tumor size 6 to 7 cm.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Kaplan-Meier analysis for propensity score–matched patients with NSCLC with a tumor size of 3.1 to 3.9 cm by adjuvant chemotherapy status.
Journal of Thoracic Oncology  , DOI: ( /j.jtho )
Copyright © 2016 International Association for the Study of Lung Cancer Terms and Conditions